High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma

Therapy options for patients with metastatic melanoma (MM) have considerably improved over the past decade. However, many patients still need effective therapy after unsuccessful immunotherapy, especially patients with BRAF-negative tumors who lack the option of targeted treatment second line. There...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohtamäki, Laura, Arjama, Mariliina, Mäkelä, Siru, Ianevski, Philipp, Välimäki, Katja, Juteau, Susanna, Ilmonen, Suvi, Ungureanu, Daniela, Kallioniemi, Olli, Murumägi, Astrid, Hernberg, Micaela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633005/
https://www.ncbi.nlm.nih.gov/pubmed/34837846
http://dx.doi.org/10.1016/j.tranon.2021.101290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633005/
https://www.ncbi.nlm.nih.gov/pubmed/34837846
http://dx.doi.org/10.1016/j.tranon.2021.101290

Ejemplares similares